DDInter1261 DDInter782
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neratinib
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Conivaptan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Stiripentol
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Naloxegol may lead to a major life threatening interaction when taken with Conivaptan
Naloxegol may lead to a major life threatening interaction when taken with Stiripentol